CMS
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Home
  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
  • News
    • Company News
    • Partner News
  • Investors
    • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Partnering
  • Contact
    • Contact Information
    • Join Us
  • EN
  • CN
Won the “Most Valuable Pharmaceutical Listing Company” from Golden Hong Kong Listed Companies for three consecutive years
2022-07-08

Won the “Most Valuable Pharmaceutical Listing Company” from Golden Hong Kong Listed Companies for three consecutive years

Selected as “Most Attractive Hong Kong Stock-Connect Companies for Institutional Investors”

Selected as “Most Attractive Hong Kong Stock-Connect Companies for Institutional Investors”

Recognized as the “Honored Company” by the Institutional Investors Magazine

Recognized as the “Honored Company” by the Institutional Investors Magazine

Won the “Hong Kong Stock-Connect Company with the Most Substantial Growth Potential” award in Golden Wing Award held by Securities Times

Won the “Hong Kong Stock-Connect Company with the Most Substantial Growth Potential” award in Golden Wing Award held by Securities Times

Awarded the “Shenzhen’s Most Potential Employer”

Awarded the “Shenzhen’s Most Potential Employer”

Invested in four overseas biotech companies including Neurelis, Acticor Biotech, Blueberry Therapeutics and VAXIMM, and acquired assets or product rights of four innovative products including Diazepam Nasal Spray, ACT017 (anti-platelet humanized monoclonal antibody), BB2603 (terbinafine-nano spray) and VXM01 (oral T-cell immune agonist) in Mainland China and/or other countries or regions

Invested in four overseas biotech companies including Neurelis, Acticor Biotech, Blueberry Therapeutics and VAXIMM, and acquired assets or product rights of four innovative products including Diazepam Nasal Spray, ACT017 (anti-platelet humanized monoclonal antibody), BB2603 (terbinafine-nano spray) and VXM01 (oral T-cell immune agonist) in Mainland China and/or other countries or regions

Acquired product rights of two innovative products including novel lead small molecule compounds CF101 and CF102 in Mainland China and/or other countries or regions

Acquired product rights of two innovative products including novel lead small molecule compounds CF101 and CF102 in Mainland China and/or other countries or regions

Acquired assets of PoNS (portable neuromodulation stimulator) in Mainland China and/or other countries or regions

Acquired assets of PoNS (portable neuromodulation stimulator) in Mainland China and/or other countries or regions

  • About Us
    • CMS Overview
    • Leadership
    • Milestones
    • Social Responsibility
  • Innovation
    • R&D Overview
    • Pipeline
  • Business
    • Business Overview
    • Cardio-cerebrovascular and Gastroenterology
    • Dermatology and Medical Aesthetics
    • Ophthalmology
    • Southeast Asia Business
  • News
    • Company News
    • Partner News
  • Investors
    • Stock Infomation
    • Financial Highlights
    • Information Disclosure
    • Corporate Governance
    • Investor Communication
  • Privacy
  • Terms Of Use
All rights reserved by CMS Group 2001-2022 ERP of CMS Group
互联网药品信息服务资格证书编号:(粤)-非经营性-2021-0109| 粤ICP备18157737号| 粤公网安备 44030502003605号